Guo-jie Ye, Ph.D.
Chief Scientific Officer
Dr. Guo-jie Ye is the Co-founder and Chief Scientific Officer of Exegenesis Bio. He has served as a Director, or Executive Director at AGTC, a publicly traded gene therapy company for 15 years. At AGTC, he was responsible for all preclinical activities including IND-enabling GLP toxicology and pharmacology studies that led to consecutively successful submissions/approval of 4 INDs in 3 years for inherited retinal disorders from FDA. Dr. Ye also served as a Senior Scientist at MediGene Inc., responsible for oncolytic HSV development. Dr. Ye earned his PhD degree from Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences and received postdoctoral training in Molecular Biology at Cornell University Medical College and Molecular Genetics of HSV in the lab of Bernard Roizman at The University of Chicago.
Dr. Ye was the Principal Investigator of a STTR grant from NIH, Co-principal Investigator of a joint program awarded by Juvenile Diabetes Research Foundation. He has been granted 4 PCT patents, published 1 book chapter and first or corresponding authored more than half of his 30+ research articles.